Our Products

Artisan is committed to bringing novel, first-in-class critical-care and hospital-based therapeutics to patients, treating physicians and payors worldwide. Our first product, ART 123, is a novel, recombinant, human and soluble thrombomodulin — and the only drug under development for DIC (disseminated intravascular coagulation) in sepsis.

DIC entails the widespread formation of microthrombi, ultimately involving organ dysfunction and death. This severe condition frequently occurs in sepsis patients, who number more than 1.8 million each year between the U.S. and Europe. About 30% of sepsis patients develop DIC, which doubles their risk of death.

ART 123 is particularly well-suited to treat DIC in sepsis because this condition is a disorder of both systemic inflammatory and coagulation pathways. ART 123 targets both of these pathways in a highly synergistic way.

The Japanese Pharmaceutical and Medical Device Agency approved Artisan’s lead drug, ART-123 (human, soluble, recombinant thrombomodulin), on January 25, 2008 for the treatment of disseminated intravascular coagulation (“DIC”) in Japan.  We are currently conducting a global Phase 2b study of ART-123 in DIC in patients with Sepsis, “A Randomized, Double–Blind, Placebo–Controlled, Phase-2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation”.  Over 150 sites worldwide are participating in this study which will recruit 750 subjects. 

Artisan has recruited an ART 123 Program Advisory Board to assist us in developing the product in a manner most beneficial to patients. These investigators, who represent some of the most renowned researchers in sepsis, critical care and hematology, will be invaluable in the strategic design and implementation of our development program. Learn about the ART 123 Program Advisory Board.

Looking Ahead
In addition to ART 123, we aim to acquire other late-stage or marketed products in the area of critical-care and hospital-based therapeutics. With our management's deep experience in both international product development and strategic alliance management, we believe we can be superior partners in product and commercial development for the long-term.

We invite interested parties to learn more by contacting us at 781.419.1919 or info@artisanpharma.net.